Drugs regulator approves BE-PCV14 vaccine to protect infants against Streptococcus pneumoniae infection
Biological E. Limited (BE), a Hyderabad-based Pharmaceutical and Vaccine Company Friday announced that its 14-valent pediatric Pneumococcal Conjugate Vaccine, (Investigational Pneumococcal Polysaccharide Conjugate Vaccine PCV14) against S. pneumoniae infection has received approval from the Drugs Controller General of India (DCGI) for manufacture and commercialization in India.
PCV14 may be administered to infants 6, 10, and 14 weeks of age in 3 doses.
Streptococcus pneumoniae infection remains one of the leading causes of death among children under the age of five in India and in developing countries. BE’s PCV14 Vaccine will help prevent invasive pneumococcal infection and save millions of lives worldwide, the company stated.
Mahima Datla, Managing Director, Biological E. Limited, said, “We are pleased with this important approval, which will help save the lives of millions of children in India and around the world. A BE’s PCV14 will contribute to the prevention of invasive pneumococcal disease. With this endorsement, our country has another essential pediatric vaccine. We will be working with regulators in other countries to make our vaccine available globally.”
BE’s PCV14 contains 14 serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F). BE’s PCV14 contains the largest number of serotypes in India and offers expanded protection against two new serotypes 22F and 33F. These new serotypes have been reported recently to be causing infections. In a Phase 3 infants trial BE’s PCV14 was non-inferior to all the common serotypes present in the comparator’s vaccine.
The primary immunogenicity objective of demonstrating non-inferiority with anti-PnCPS IgG antibody concentrations against each of the 12 common serotypes of BE-PCV14 vaccine in terms of subjects seroconverted and the ratio of geometric mean concentrations against corresponding serotypes in active comparator was met. Non-inferiority was demonstrated with anti-PnCPS IgG antibody concentrations against unique serotypes 22F and 33F specific to BE-PCV14.
The safety comparison demonstrates that the BE-PCV14 vaccine was well-tolerated and considered safe. BE’s PCV14 is comparable in terms of serotype coverage for infants to the two globally approved pneumococcal conjugate vaccines Prevenar13 and Merck’s VAXNEUVANCE.
[With Inputs from IANS]
PGurus is now on Telegram. Click here to join our channel and stay updated with all the latest news and views
For all the latest updates, download PGurus App.
- IIT Delhi shows game-changing technologies to German Defence Minister - June 7, 2023
- Adani Group shows record-breaking performance across portfolios; EBITDA grows at 36% to Rs.57,219 cr - June 7, 2023
- Partnership with India one of the most consequential, says US principal deputy spokesperson - June 7, 2023